216 related articles for article (PubMed ID: 28919470)
1. Preparation and characterization of amorphous ciprofloxacin-amino acid salts.
Mesallati H; Conroy D; Hudson S; Tajber L
Eur J Pharm Biopharm; 2017 Dec; 121():73-89. PubMed ID: 28919470
[TBL] [Abstract][Full Text] [Related]
2. Polymer/Amorphous Salt Solid Dispersions of Ciprofloxacin.
Mesallati H; Tajber L
Pharm Res; 2017 Nov; 34(11):2425-2439. PubMed ID: 28875408
[TBL] [Abstract][Full Text] [Related]
3. Amorphous Polymeric Drug Salts as Ionic Solid Dispersion Forms of Ciprofloxacin.
Mesallati H; Umerska A; Paluch KJ; Tajber L
Mol Pharm; 2017 Jul; 14(7):2209-2223. PubMed ID: 28570079
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
5. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
[TBL] [Abstract][Full Text] [Related]
7. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability.
Laitinen R; Löbmann K; Grohganz H; Strachan C; Rades T
Mol Pharm; 2014 Jul; 11(7):2381-9. PubMed ID: 24852326
[TBL] [Abstract][Full Text] [Related]
9. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
[TBL] [Abstract][Full Text] [Related]
10. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
11. Formation and physicochemical properties of crystalline and amorphous salts with different stoichiometries formed between ciprofloxacin and succinic acid.
Paluch KJ; McCabe T; Müller-Bunz H; Corrigan OI; Healy AM; Tajber L
Mol Pharm; 2013 Oct; 10(10):3640-54. PubMed ID: 23947816
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolone Amorphous Polymeric Salts and Dispersions for Veterinary Uses.
Mesallati H; Umerska A; Tajber L
Pharmaceutics; 2019 Jun; 11(6):. PubMed ID: 31181834
[TBL] [Abstract][Full Text] [Related]
13. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs--Part 2: molecular interactions.
Löbmann K; Laitinen R; Strachan C; Rades T; Grohganz H
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):882-8. PubMed ID: 23567485
[TBL] [Abstract][Full Text] [Related]
14. Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin.
Ojarinta R; Heikkinen AT; Sievänen E; Laitinen R
Eur J Pharm Biopharm; 2017 Mar; 112():85-95. PubMed ID: 27888143
[TBL] [Abstract][Full Text] [Related]
15. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
16. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
Ruponen M; Visti M; Ojarinta R; Laitinen R
Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
[TBL] [Abstract][Full Text] [Related]
17. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
Wu W; Grohganz H; Rades T; Löbmann K
Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
[TBL] [Abstract][Full Text] [Related]
18. In Situ Salification in Polar Solvents: a Paradigm for Enabling Drug Delivery of Weakly Ionic Drugs as Amorphous Solid Dispersion.
Nair R; Lamare I; Tiwari NK; Ravi PR; Pillai R
AAPS PharmSciTech; 2018 Jan; 19(1):326-337. PubMed ID: 28721630
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of multi-component tablets containing co-amorphous salts: Combining multimodal non-linear optical imaging with established analytical methods.
Ojarinta R; Saarinen J; Strachan CJ; Korhonen O; Laitinen R
Eur J Pharm Biopharm; 2018 Nov; 132():112-126. PubMed ID: 30248394
[TBL] [Abstract][Full Text] [Related]
20. Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement.
Branham ML; Moyo T; Govender T
Eur J Pharm Biopharm; 2012 Jan; 80(1):194-202. PubMed ID: 21906676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
